Pemetrexed-induced eyelid edema: Incidence and clinical manifestations

Anticancer Research

Volumn 30, Issue 12, 2010, Pages 5185-5188

  Schallier, D ^a   Decoster, L ^a   Fontaine, C ^a   De Greve J ^a  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Eyelid edema; Pemetrexed; Retrospective study

Indexed keywords

CARBOPLATIN; CISPLATIN; PEMETREXED;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; EYELID EDEMA; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; EDEMA; EYELID DISEASES; EYELIDS; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 78751496742     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffle P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikira and Paoletti P: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644, 2003.
2. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, Von Pawel J, Gatzemeier U, Tsao TC, Pless M, Muller T, Lim HL, Desch C, Szondi K, Gervais R, Shahazyar, Manegold C, Paul S, Paoletti P, Einhorn L andBunn PA: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589-1597, 2004.
3. Scagliotti GV, Parikh P, Von Pawel J, Biesma B, Vansteenkiste J, Manegold C, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP and Gándara D: Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small cell lung cancer. J Clin Oncol 26: 3543-3551, 2008.
4. Common Terminology Criteria for Adverse Events v. 3.0, June 10, 2003.
5. Kurata T, Tamura K, Okamoto I, Satoh T, Nakagawa K and Fukuoka M: Pemetrexed-induced edema of the eyelid. Lung Cancer 54: 241-242, 2006.
6. Guhl G, Diaz-Ley B, Sanchez-Perez J, Jimenez U and GarciaDiez A: Pemetrexed-induced edema of the eyelid. Lung Cancer 69 (2): 249-250, 2010.
7. Bastos DA, Calabrien A and Katz A: Pemetrexed-induced fluid retention. J Thoracic Oncol 5 (5): 752, 2010.
8. Semb KA, Aamdal S and Oian P: Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 16: 3426-3432, 1998.
9. Piccart M, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, Bontenbal M, Awada A, Selleslags J, Van Vreckem A and Van Glabbeke M: Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 15 (9): 3149-3155, 1997.
10. Maalouf T, Angioi K, Champigneulle A, Guerci A and George JL: Palpebral edema secondary to treatment by a specific inhibitor of tyrosine kinase: Glivec. A case report. J Fr Ophtalmol 27 (1): 107109, 2004.
11. Casali PG, Joensuu H, Martin Broto J, Garcia del Muro X, Blay J, May C and Reichardt P: Preliminary data of nilotinib in the first-line treatment of patients with metastatic or unresectable gastrointestinal stromal tumors (GIST). J Clin Oncol 28 (15S): TPS332, 64s, 2010.
12. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Trekova V, Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP, Peterson P, John WJ, Krejcy K and Belani CP: Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung cancer (NSCLC). Lancet 374 (9699): 1432-1440, 2009.